Marker
(% cells)
Healthy donors (n=13) TB patients
The total group
( n=27)
 PPD-responsive
(n=17)
PPD-anergic
(n=10 )
CD14+ 8.7 ± 1.4 19.6 ± 2.5 * 17.2 ± 2.7 * 30.0 ± 5.4 *#
CD25+ 25.1 ± 3.5 9.6 ± 1.2 * 8.8 ± 1.3 * 12.1 ± 2.9 *
CD1a+ 11.8 ± 2.5 11.8 ± 1.4 10.7 ± 1.4 14.6 ± 3.7
CD83+ 23.3 ± 2.7 32.4 ± 2.9 34.2 ± 3.7 27.8 ± 3.4
CD11c+ 28.3 ± 2.6 30.2 ± 2.7 29.5 ± 3.2 34.2 ± 5.3
CD123+ 27.5 ± 2.3 25.2 ± 1.8 24.0 ± 2.0 25.0 ± 2.7
CD1a+CD83- 6.9 ± 2.0 5.3 ± 0.8 4.5 ± 0.7 7.5 ± 2.0
CD1a+CD83+ 5.0 ± 1.0 6.5 ± 1.0 6.2 ± 1.1 7.1 ± 2.3
CD1a-CD83+ 18.9 ± 2.6 25.9 ± 2.8 28.0 ± 3.6 20.7 ± 2.9
Note: Analysis of IFN-DC phenotype was performed by one- or two-color flow cytometry assays using FITC-, PE- or APC-conjugated antibodies (CD1a, CD11c, CD14, CD25, CD83, CD123; Pharmingen, USA). * - pU <0.05 vs healthy donors; # - pU <0.05 vs PPD-responsive patients.
Table 2: Immunophenotypic characteristics of patient IFN-DCs.